The Illinois Wellness Insider
SEE OTHER BRANDS

Informing on health and wellness news in Illinois

The Illinois Wellness Insider: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Illinois Wellness Insider.

Press releases published on August 14, 2025

CooperCompanies to Participate in the Wells Fargo Healthcare Conference

CooperCompanies to Participate in the Wells Fargo Healthcare Conference

SAN RAMON, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025. Al White, President …

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a …

Milestone Scientific Achieves 25% Increase in Revenue for the Second Quarter of 2025

Milestone Scientific Achieves 25% Increase in Revenue for the Second Quarter of 2025

ROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial …

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results

POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for …

Shuttle Pharma Provides Second Quarter 2025 Corporate Update

Shuttle Pharma Provides Second Quarter 2025 Corporate Update

GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer …

CMMB, with P&G Support, Responds to Deadly Cholera and Hunger Crisis in South Sudan

CMMB, with P&G Support, Responds to Deadly Cholera and Hunger Crisis in South Sudan

Juba, South Sudan, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Catholic Medical Mission Board (CMMB) is launching an emergency response in South Sudan as compounding crises threaten thousands of lives in Upper Nile region and Central Equatoria State. The devastating …

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales of …

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt …

GT Biopharma Reports Second Quarter 2025 Financial Results

GT Biopharma Reports Second Quarter 2025 Financial Results

GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and initiated dosing of the fifth patient in the study; …

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

–  Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients progressing well with preliminary data in second half of 2025 and first half of 2026 –  Phase 1/ …

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

Presented positive translational data from SYNGAP1-related disorders program showcasing efficacy in a humanized SYNGAP mouse model and increased protein in non-human primates at the 28th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting …

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025

PORTLAND, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …

Venus Concept Announces Second Quarter 2025 Financial Results

Venus Concept Announces Second Quarter 2025 Financial Results

TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2025. Summary of …

Nasus Pharma Announces Closing of Initial Public Offering

Nasus Pharma Announces Closing of Initial Public Offering

TEL AVIV, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions …

Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption submission to FDA of novel CBGM technology in Q4 …

Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption

Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption

EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“ …

TOMI Environmental Solutions, Inc. Reports Q2 2025 Financial Results and Outlines Growth Initiatives

TOMI Environmental Solutions, Inc. Reports Q2 2025 Financial Results and Outlines Growth Initiatives

FREDERICK, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and decontamination essentials through its premier Binary Ionization Technology® (BIT™) platform, today announced …

Profound Medical Announces Second Quarter 2025 Financial Results

Profound Medical Announces Second Quarter 2025 Financial Results

TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation …

RxSight, Inc. to Present at the Wells Fargo Healthcare Conference

RxSight, Inc. to Present at the Wells Fargo Healthcare Conference

ALISO VIEJO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming …

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Announced clinical improvement in progression free survival observed in pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (pembrolizumab) for the treatment of first-line advanced melanoma, but statistical significance narrowly missed; company plans to meet …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions